The Scientific Advisory Board (SAB) for UK DRI HQ will help look critically and imaginatively at our science portfolio and also advise on our structure, size, growth and ambition.
5
members of the UK DRI HQ SAB
Fred (Rusty) Gage
President, Salk institute, Adler Professor for Research an Age-Related Neurodegenerative Diseases
“The UK Dementia Research Institute is a nationwide interdisciplinary effort to address one of the most pressing issues of this and the coming generations, not just in the UK but worldwide. I am pleased to join the Scientific Advisory Board to help advise the leadership of the Institute in an effort to make a difference both in the short term as well as for the long term. The stakes are high, and I believe the approach UK DRI is taking can make a difference if managed and advised wisely."
Alison Goate
Director, Centre on Alzheimer's Disease at Icahn School of Medicine at Mount Sinai, NYC – Professor (endowed chair) of neurogenetics, Icahn School of Medicine at Mount Sinai
“I am honoured and delighted to serve on the UK DRI SAB. The institute is a very important national initiative focused on understanding molecular mechanisms of neurodegenerative disease with the goal of improving treatment for these devastating disorders.”
Stacie Weninger
President, FBRI (Fidelity Biosciences Res Initiative, a division of the VC Fidelity Biosciences)
“It is clear that we need an innovative, collaborative approach to advance our understanding of the fundamental causes of dementia in order to develop effective diagnostics and treatments for these devastating illnesses. I am proud to be working with the UK DRI as it takes on bold, collaborative initiatives to further our knowledge and enable the development of much needed therapeutics.”
Eric Karran
Vice President and Director, Cambridge Research Center, Abbvie
“I am very pleased to be given the opportunity to join the UK DRI Scientific Advisory Board and to be able to contribute to the success of the institute. Breakthroughs in our understanding of neurodegenerative disease processes are essential if we are to find effective therapeutic interventions for these devastating diseases.”
Jo Bury
Managing director, VIB-KU Leuven
“Finding treatments for dementia is an immense medical need, not only for the patients but also for their families and environment. To be able to help the millions of people involved, we need to get a better insight into the functioning of the brain in health and in degeneration. The UK DRI comes at the right moment to capitalise on new disruptive technologies to break the code of the unknown. I am thrilled to be able to contribute to such an endeavour”.
Article published: 10 Dec 2019
